Figure 1.
Profile summarizing the trial flow.
CI = confidence interval; EGFR = epidermal growth factor receptor; HR = Hazard ratio; PFS = progression-free survival; TKI = tyrosine kinase inhibitor.
Table 1.
Characteristics of included studies for indirect meta-analysis.
Table 2.
Characteristics of included studies for direct meta-analysis.
Figure 2.
Direct comparison of TKI versus chemotherapy in EGFR exon 19 deletions cohort in terms of HR for PFS. CI = confidence interval; EGFR = epidermal growth factor receptor; HR = Hazard ratio; PFS = progression-free survival; TKI = tyrosine kinase inhibitor.
Figure 3.
Direct comparison of TKI versus chemotherapy in EGFR exon 21 L858R mutations cohort in terms of HR for PFS. CI = confidence interval; EGFR = epidermal growth factor receptor; HR = Hazard ratio; PFS = progression-free survival; TKI = tyrosine kinase inhibitor.
Figure 4.
Geometric distribution of indirect comparisons.
Solid lines between regimens represented the existence of direct comparisons. Chemo = chemotherapy; EGFR = epidermal growth factor receptor; TKI = tyrosine kinase inhibitor.
Table 3.
Indirect comparison of EGFR exon 19 deletion versus EGFR exon 21 L858R mutation in TKI therapy cohort in terms of HR for PFS.
Figure 5.
Direct comparison of EGFR exon 19 deletions versus EGFR exon 21 L858R mutations in TKI therapy cohort in terms of HR for PFS. CI = confidence interval; EGFR = epidermal growth factor receptor; HR = Hazard ratio; PFS = progression-free survival; TKI = tyrosine kinase inhibitor.